Keywords: Celgene, Avila Therapeutics, M&A, Protein silencing, Financial results 2011, Hematological cancers

Celgene to buy Avila; posts strong 4th-qtr results

Article | 27 January 2012

Print This

USA-based Celgene (Nasdaq: CELG) yesterday revealed that it has entered into a definitive merger deal to acquire Avila Therapeutics, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in